Posts

Electra Targets Nearly $300M IPO

on

AstraZeneca’s Camizestrant Misses Key First-Line Breast-Cancer Trial Goal

on

Amgen’s Imdelltra lands major new lung cancer victory

on

FDA approves AstraZeneca’s oral SERD camizestrant despite negative advisory-panel vote

on

Wainua failure sharpens—but does not settle—the TTR silencer versus stabilizer debate

on

AstraZeneca’s AZD5462 revives interest in relaxin-based heart-failure treatment

on

Recent US COPD Medical Affairs Reputation News

on

Tezspire scores Phase 3 win in eosinophilic esophagitis, challenging Dupixent

on

Will EU prescribers be swayed by AstraZeneca’s Etcamah case?

on

Enhertu gains a potential first-line foothold in HER2-mutant NSCLC, but oral TKIs remain credible competitors

on

AstraZeneca touts Enhertu, Orpathys dual lung cancer wins amid bispecific failure (August 17, 2026)

on

AstraZeneca Cans Late-Stage Bispecific Trial After Lung Cancer Setback

on

ICER Says AstraZeneca's New Blood Pressure Drug Baxfendy Is Not Cost-Effective

on

Merger talks between AstraZeneca and Bristol Myers Squibb are off, report says

on

Post-Hoc Live: Who wants an AstraZeneca-Bristol Myers megadeal?

on

Pathos AI pads pipeline with $2.2B Alphamab deal and new AstraZeneca partnership

on

Editors Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea summarized and explained

on

AstraZeneca and Bristol Myers Squibb in $400 Billion Merger Talks

on

AstraZeneca foresees blockbuster sales for Claudin 18.2 ADC, but Ultomiris flops in rare disease

on

AZ stays on track for $80B revenue goal as cancer meds, rare disease sales help offset Ultomiris miss

on